Novo Nordisk (NYSE:NVO) slashes capital, cancels 45M shares

Grafa
04-25

Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024.

The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10.

This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800. 

Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.

Claim Now

Can LLY & NVO Continue to Thrive After Earnings?
LLY and NVO will release their financial reports this Tuesday and Thursday. Both of these weight-loss drug companies have risen by over 20% since the beginning of the year. ---------------------- Is weight-loss drug, like AI, a main investment theme this year? Would you buy weight-loss drug companies? Can Eil Lilly return to $800?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment